Donaldson Capital Management LLC Sells 4,670 Shares of Amgen Inc. (NASDAQ:AMGN)

Donaldson Capital Management LLC reduced its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 29.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 11,057 shares of the medical research company's stock after selling 4,670 shares during the quarter. Donaldson Capital Management LLC's holdings in Amgen were worth $3,185,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in AMGN. Flputnam Investment Management Co. lifted its stake in Amgen by 0.7% in the fourth quarter. Flputnam Investment Management Co. now owns 53,704 shares of the medical research company's stock valued at $15,468,000 after acquiring an additional 397 shares during the last quarter. Legacy CG LLC lifted its stake in Amgen by 63.2% in the fourth quarter. Legacy CG LLC now owns 22,152 shares of the medical research company's stock valued at $6,380,000 after acquiring an additional 8,581 shares during the last quarter. Keel Point LLC lifted its stake in Amgen by 5.3% in the fourth quarter. Keel Point LLC now owns 2,123 shares of the medical research company's stock valued at $611,000 after acquiring an additional 107 shares during the last quarter. Aurora Private Wealth Inc. acquired a new stake in Amgen in the fourth quarter valued at approximately $247,000. Finally, Bourgeon Capital Management LLC lifted its stake in Amgen by 54.5% in the fourth quarter. Bourgeon Capital Management LLC now owns 42,258 shares of the medical research company's stock valued at $12,171,000 after acquiring an additional 14,903 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

AMGN has been the subject of a number of analyst reports. Raymond James initiated coverage on shares of Amgen in a research note on Thursday, March 28th. They issued a "market perform" rating for the company. SVB Leerink lowered shares of Amgen from an "outperform" rating to a "market perform" rating and dropped their price target for the company from $324.00 to $318.00 in a research report on Wednesday, February 7th. Oppenheimer reissued an "outperform" rating and issued a $350.00 price target on shares of Amgen in a research report on Thursday, February 1st. The Goldman Sachs Group lifted their price target on shares of Amgen from $313.00 to $350.00 and gave the company a "buy" rating in a research report on Wednesday, February 7th. Finally, Truist Financial reissued a "buy" rating and issued a $320.00 price target on shares of Amgen in a research report on Friday. Ten research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat.com, Amgen currently has an average rating of "Hold" and a consensus price target of $295.30.

Amgen Price Performance

Shares of NASDAQ:AMGN traded down $1.77 on Monday, hitting $265.51. The stock had a trading volume of 1,731,820 shares, compared to its average volume of 2,883,643. Amgen Inc. has a twelve month low of $211.71 and a twelve month high of $329.72. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65. The firm's 50 day moving average price is $279.63 and its 200-day moving average price is $281.52. The company has a market capitalization of $142.29 billion, a price-to-earnings ratio of 21.26, a price-to-earnings-growth ratio of 2.53 and a beta of 0.58.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.66 by $0.05. The business had revenue of $8.20 billion for the quarter, compared to the consensus estimate of $8.13 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The firm's quarterly revenue was up 19.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $4.09 EPS. On average, equities research analysts predict that Amgen Inc. will post 19.49 earnings per share for the current year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be given a dividend of $2.25 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $9.00 annualized dividend and a yield of 3.39%. Amgen's dividend payout ratio (DPR) is 72.06%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.